Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IPDOX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN115429893A ADC16
|
|||||
| Synonyms |
CN115429893A ADC16
Click to Show/Hide
|
|||||
| Organization |
Bio Thera Solutions Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
FR-alpha antibody
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
CN115429893A ADC1 Payload
|
Payload Info | ||||
| Linker Name |
CB07 linker
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
86.81
|
%
|
Undisclosed | Undisclosed |
| Tumor Growth lnhibition value (TGl) |
86.81
|
%
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 86.81% | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
In the OV3756 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | OV3756 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 86.81% | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
In the OV3756 xenograft model, the ADCs were administered at 2.5 mg/kg (once, IV).
|
||||
| In Vivo Model | OV3756 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.645 nM | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
MCF-7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC16 (4x the first top concentration at 250 nM) for 5 days.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.645 nM | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
MCF-7 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC16 (4x the first top concentration at 250 nM) for 5 days.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.611 nM | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
JEG-3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC16 (4x the first top concentration at 1000 nM) for 5 days.
|
||||
| In Vitro Model | Gestational choriocarcinoma | JEG-3 cells | CVCL_0363 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.611 nM | Positive FR-alpha expression (FR-alpha+++/++) | ||
| Method Description |
JEG-3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC16 (4x the first top concentration at 1000 nM) for 5 days.
|
||||
| In Vitro Model | Gestational choriocarcinoma | JEG-3 cells | CVCL_0363 | ||